Shinobi Therapeutics secures $59M grant for iPS-T cell therapy
Shinobi Therapeutics has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The funds will support the development of Shinobi’s lead iPS-T cell programme targeting GPC3+ tumours. Shinobi also announced an extension of… Read More